Stanford University School of Medicine neuroscientists have demonstrated, in a study to be published online April 24 in Stroke, that a compound mimicking a key activity of a hefty, brain-based protein is capable of increasing ...
Apr 24, 2012
0
0
The mechanical resistance of tumors and collateral damage of standard treatments often hinder efforts to defeat cancers. A team of researchers from CNRS, the French National Institute of Health and Medical Research (INSERM), ...
Jan 3, 2017
0
2
An international team led by scientists at The Scripps Research Institute (TSRI) has determined and analyzed the three-dimensional atomic structure of the human glucagon receptor. The receptor, found mainly on liver and kidney ...
Jul 17, 2013
0
0
A new study on prostate cancer describes a novel class of drugs developed by UT Southwestern Medical Center researchers that interrupts critical signaling needed for prostate cancer cells to grow.
May 28, 2013
0
0
The research thoroughly reviews the importance of the blood-brain barrier (BBB) and the blood-tumor barrier (BTB) along with the current status and future perspectives of interesting physical and surgical strategies to circumvent ...
Mar 9, 2016
0
12
(HealthDay)—Although the first description of a rapidly progressive nephropathy associated with the consumption of aristolochic acid (AA) found in Chinese herbs was first reported 20 years ago, AA-induced nephropathy remains ...
Mar 19, 2013
0
0
A team of researchers at Case Western Reserve University School of Medicine has developed the first "theranostic" agent for the treatment of acute lymphoblastic leukemia (ALL). ALL is the most common type of childhood cancer ...
Mar 7, 2012
0
0
The treatment of central nervous system (CNS) diseases can be particularly challenging because many of the therapeutic agents such as recombinant proteins and gene medicines are not easily transported across the blood-brain ...
Feb 1, 2013
0
0
Scientists from the Jupiter campus of The Scripps Research Institute (TSRI) have shown a novel way to dramatically raise the potency of drug candidates targeting RNA, resulting in a 2,500-fold improvement in potency and significantly ...
Aug 6, 2013
0
0
The U.S. Food and Drug Administration approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for treatment of adults with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer ...
Apr 14, 2022
0
2
